Mer­ck adds third cer­vi­cal can­cer nod for Keytru­da, bring­ing to­tal ap­provals to 39

Mer­ck’s Keytru­da scored its third US ap­proval in cer­vi­cal can­cer, mak­ing it the first and on­ly an­ti-PD-1 ther­a­py ap­proved as a com­bi­na­tion with chemora­dio­ther­a­py for pa­tients with FI­GO 2014 stage III-IVA cer­vi­cal can­cer.

The FDA added an­oth­er in­di­ca­tion to Mer­ck’s block­buster based on da­ta from the 1,060-pa­tient Phase III KEYNOTE-A18 tri­al. In the study, the com­bi­na­tion re­duced the risk of dis­ease pro­gres­sion or death by 41% com­pared to place­bo plus chemora­dio­ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER